Abstract:A novel aminoquinazolin derivative (named 9d), synthesized in our lab shows potential antitumor activity against A549 lung cancer cell lines. However, previous studies on the pharmacological mechanism of 9d mostly focused on cell and gene levels; the metabolic mechanism remains unknown. In this paper, an ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF MS) based metabolomics approach was established to study the probable antitumor mechanism. Q-TOF MS and MS/MS were used to identify significantly different metabolites. 22 significantly different metabolites were observed between the 9d-treated A549 lung cells group and control group. They were involved in glycerophospholipid metabolism, glutathione metabolism, phenylalanine metabolism, cysteine and methionine metabolism, and aminoacyl-tRNA biosynthesis. The results showed that glutathione level and cell-membrane components phosphatidylcholines were decreased in 9d-treated cells, while their oxidative products, oxidized glutathione and lysophosphatidylcholines, were significantly increased. Further biological investigation showed an apparent accumulation of reactive oxygen species and a decrease in mitochondrial membrane potential. The results indicated that the aminoquinazolin derivative induced oxidative stress-mediated apoptosis. Moreover, phenylalanine metabolism suggested the up-regulation of L-phenylalanine might act as an endogenous drug carrier of 9d to improve cellular antiproliferation ability. The inhibition of aminoacyltransfer RNA and flow cytometry results indicated that cell cycle progression was blocked in the G1 phase, which was in accordance with the results obtained from some marketed aminoquinazolin derivatives. The above results proposed that 9d could induce oxidative stress and cell cycle arrest, which finally led to cell apoptosis in A549 cells. The study supplies a rapidly and highly active strategy to investigate the antitumor mechanism of drugs, which benefits its further improvement and development.

Q39, A Quinoxaline 1,4-Di-N-Oxide Derivative, Inhibits Hypoxia-Inducible Factor-1 Alpha Expression And The Akt/Mtor/4e-Bp1 Signaling Pathway In Human Hepatoma Cells

Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells

Q39, a novel synthetic Quinoxaline 1,4-Di-N-oxide compound with anti-cancer activity in hypoxia.

Novel Hypoxia-slective Compound Q39 Induced Bel-7402 Cell Apoptosis via Blocking HIF-1 Translocation

Q39 induces apoptosis in human leukemia cell line K562 in hypoxia

Correlation of Pharmacokinetic Features and Tissue Distribution with Toxicity of Q39, a Hypoxic Cell Cytotoxic Agent.

Synthesis And Biological Evaluation Of 3-Aryl-Quinoxaline-2-Carbonitrile 1,4-Di-N-Oxide Derivatives As Hypoxic Selective Anti-Tumor Agents

Synthesis and Biological Evaluation of 3-Aryl-quinoxaline-2-carbonitrile 1,4-Di-<em>N</em>-oxide Derivatives as Hypoxic Selective Anti-tumor Agents

Q6, a Novel Hypoxia-Targeted Drug, Regulates Hypoxia-Inducible Factor Signaling Via an Autophagy-Dependent Mechanism in Hepatocellular Carcinoma

Synthesis and Cytotoxic Activity of 3-Phenyl-2-thio-quinoxaline 1,4-Dioxide Derivatives in Hypoxia and in Normoxia.

Design, Synthesis and Biological Evaluation of 6-(Nitroimidazole-1h-alkyloxyl)-4-anilinoquinazolines As Efficient EGFR Inhibitors Exerting Cytotoxic Effects Both under Normoxia and Hypoxia.

Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.

ZDQ-0620, a Novel Phosphatidylinositol 3-Kinase Inhibitor, Inhibits Colorectal Carcinoma Cell Proliferation and Suppresses Angiogenesis by Attenuating PI3K/AKT/mTOR Pathway

Hypoxia-selective cytotoxicity and radiosensitization of quinoxaline 1,4-di-N-oxide derivative, QN-2013

Design, Synthesis, and Biological Study of 4-[(2-nitroimidazole-1h-alkyloxyl)aniline]-quinazolines As EGFR Inhibitors Exerting Cytotoxicities Both under Normoxia and Hypoxia.

The Quinazoline Derivative, 04NB-03, Induces Cell Cycle Arrest and Apoptosis in Hepatocellular Carcinoma Cells in a Reactive Oxygen Species-Dependent Manner.

A Novel Quinolinylmethyl Substituted Ethylenediamine Compound Exerts Anti-Cancer Effects Via Stimulating the Accumulation of Reactive Oxygen Species and NO in Hepatocellular Carcinoma Cells.

XQ2, a Novel TPZ Derivative, Induced G2/M Phase Arrest and Apoptosis under Hypoxia in Non-Small Cell Lung Cancer Cells

Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway

alysis reveals aminoquinazolin derivative 9 d-induced oxidative stress and cell cycle arrest in A 549 cells

Design, synthesis, and evaluation of novel ursolic acid derivatives as HIF-1α inhibitors with anticancer potential